S
Subhabrata Sen
Researcher at Shiv Nadar University
Publications - 100
Citations - 1150
Subhabrata Sen is an academic researcher from Shiv Nadar University. The author has contributed to research in topics: Chemistry & Aryl. The author has an hindex of 16, co-authored 87 publications receiving 863 citations. Previous affiliations of Subhabrata Sen include Tata Steel & Calcutta School of Tropical Medicine.
Papers
More filters
Patent
Bicyclic and bridged nitrogen heterocycles
Andrew M. K. Pennell,James B. Aggen,J. J. Kim Wright,Subhabrata Sen,Wei Chen,Daniel J. Dairaghi,Penglie Zhang +6 more
TL;DR: In this paper, a set of compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors, which are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component.
Journal ArticleDOI
Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification
Santanu Hati,Sayantan Tripathy,Pratip Kumar Dutta,Rahul Agarwal,Ramprasad Srinivasan,Ashutosh Singh,Shailja Singh,Subhabrata Sen +7 more
TL;DR: Design and synthesis of a library of compounds bearing spiro[pyrrolidine-3, 3´-oxindole] motifs that demonstrated exceptional inhibitory activity against the proliferation of MCF-7 breast cancer cells are reported.
Journal ArticleDOI
Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
Papiya Majumdar,Chandramohan Bathula,Suparna Mercy Basu,Subhendu K. Das,Rahul Agarwal,Santanu Hati,Ashutosh Singh,Subhabrata Sen,Benu Brata Das +8 more
TL;DR: A library comprising of hydantoin and thiohydantoin derivatives and thiophenyl as the central moiety exhibited potent inhibition of human Top1 (HTop1) through stabilization of Top1-DNA cleavage complexes and showed selective anticancer activity against human cervical carcinoma and breast carcinoma cell lines.
Patent
1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
Andrew M. K. Pennell,James B. Aggen,J. J. Kim Wright,Subhabrata Sen,Brian E. Mcmaster,Daniel Joseph Dairaghi,Valeri V. Martichonok +6 more
TL;DR: In this paper, aryl piperazine derivatives are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR 1.
Journal ArticleDOI
Accessing Benzimidazoles via a Ring Distortion Strategy: An Oxone Mediated Tandem Reaction of 2-Aminobenzylamines
TL;DR: In this reaction initial condensation of 2-aminobenzylamine with appropriate aldehydes afforded a tetrahydroquinazoline intermediate which underwent oxone-mediated ring distortion to afford the desired compounds in moderate to excellent yields.